Automating the Vein: Robotics Reshape the U.S. Platelet Supply

MILWAUKEE — October 19, 2026 — In the intricate, high-stakes logistics of modern healthcare, few supply chains are as fragile—or as critical—as the network that moves human blood from donor to patient. Unlike manufactured pharmaceuticals, blood components cannot be stockpiled indefinitely. This is especially true for platelets, the cell fragments essential for clotting, which carry a notoriously short shelf life of just five to seven days. For hospital administrators and regional health networks, managing this perishable inventory is a relentless, daily battle against the clock.

Today, a significant operational shift is underway to win that battle. Versiti, a massive nonprofit healthcare organization, has become the tenth U.S. blood center to adopt the Reveos Automated Blood Processing System. Manufactured by Colorado-based Terumo Blood and Cell Technologies, the device represents a fundamental disruption in how the medical industry extracts vital components from whole blood donations. By replacing manual, multi-step separation protocols with a single-cycle automated centrifuge system, the platform is poised to radically enhance platelet production capacity across Versiti’s five-state Midwestern territory.

For leaders tracking the intersection of medical technology and operational resilience, this deployment is more than a localized upgrade. It is a case study in how targeted robotics can eliminate logistical bottlenecks, optimize skilled labor, and ultimately secure a life-saving commodity in a world defined by supply chain volatility.

Solving the Shelf-Life Crisis Through Automation

Historically, separating whole blood into its constituent parts—red blood cells, plasma, and platelets—has been a labor-intensive endeavor. The traditional protocol is a highly choreographed dance involving up to 26 distinct manual steps, including precise balancing, sequential centrifugation, fluid expression, and manual data capture. Not only does this require significant hands-on time from specialized technicians, but the multi-step nature of the process inherently introduces the risk of human error and product variability.

Automated systems fundamentally rewrite this workflow. The newly adopted platform is currently the only whole blood automation device available in the United States capable of executing this three-part separation in a single, fully automated centrifugation cycle. Paired with proprietary software for seamless data integration, the technology eliminates more than half of the traditional manual steps.

One biomedical engineer familiar with the rollout noted that transitioning to this level of automation reduces hands-on processing time by over 60 percent. In clinical trials and early adoptions, automated processing dropped the total cycle time from an average of 92 minutes under semi-automated methods to just 76 minutes. Furthermore, the system incorporates LCD-guided fail-safes that physically prevent operators from advancing the process if a step is performed incorrectly, drastically reducing the rate of discarded units due to procedural errors.

This efficiency is deeply synergistic with recent regulatory advancements. In 2022, the FDA cleared specialized pooling sets that extended the viable shelf life of platelets from five days to seven days. When combined with rapid, automated extraction, blood centers can maximize that extended window, ensuring that a higher volume of viable platelets reaches hospital trauma units before expiring.

Securing the Midwest's Blood Reserves

Versiti’s footprint is vast, encompassing a network of donors and hospitals across Illinois, Indiana, Michigan, Ohio, and Wisconsin. In these regions, as in the rest of the country, the demand for platelets consistently threatens to outpace supply. Platelets are a critical requirement for patients undergoing cancer therapies, complex surgeries, and emergency trauma care.

Traditionally, the most efficient way to collect platelets has been through apheresis—a process where a donor is hooked up to a machine that extracts blood, filters out the platelets, and returns the remaining components to the donor's body. While effective, apheresis donations are time-consuming and rely on a smaller, highly dedicated donor pool. Relying solely on apheresis leaves regional supply chains vulnerable to sudden spikes in demand or dips in donor turnout.

"For patients undergoing cancer treatment, surgery or emergency care, having platelets available when needed can make a critical difference," said Karen Smith, Vice President of Blood Production and Distribution at Versiti. "Reveos helps us make the most of every blood donation by expanding our ability to produce platelets more efficiently and meet hospital demand. It's an investment in getting patients the blood products they need when they need them."

By implementing whole-blood automation, Versiti is effectively unlocking a massive secondary source of platelets. Routine whole-blood donations, which are faster and attract a much broader demographic of donors, can now be efficiently mined for platelets to supplement the apheresis supply. This dual-pronged procurement strategy creates a vital buffer, ensuring that rural hospitals and major urban oncology wards alike have access to consistent, high-quality blood components.

Catching Up: The U.S. Automation Shift

While the adoption of single-cycle automated processing is currently making headlines in the United States, the technology itself is hardly novel on the global stage. Prior to receiving clearance from the U.S. Food and Drug Administration in 2023, the Reveos system had already been deployed in 52 countries, operating successfully for more than a decade.

The prolonged pathway to U.S. commercialization highlights a common friction point in medical technology: the rigorous, often protracted nature of American regulatory approval compared to European or Asian markets. However, the 2023 FDA clearance has served as a starting gun for a modernization sprint across the domestic blood banking sector. Early adopters like The Blood Center in New Orleans and the Community Blood Center in Wisconsin paved the way, proving the operational viability of the system in the American healthcare ecosystem.

"Ten U.S. blood centers have now chosen Reveos to modernize whole blood processing, and each implementation represents progress towards a more flexible and resilient blood supply," said Maura Lienesch, Vice President, Commercial at Terumo BCT. "Versiti's reach across five states makes this an especially meaningful milestone, with the potential to help more hospitals and patients benefit from a stronger, more flexible platelet supply."

The broader market dynamics underscore this technological pivot. Industry analysts project that the global automated blood processing equipment market will surge from $50.1 billion in 2025 to over $108 billion by 2035. With North America expected to maintain dominance in this sector, the rapid adoption of automated systems by massive networks like Versiti signals that the U.S. market is finally aligning with global standards of blood processing efficiency.

The Economic and Operational Calculus

For healthcare executives, the transition to automated blood processing is not merely a clinical upgrade; it is a strategic maneuver to combat systemic labor shortages. The U.S. healthcare sector continues to face acute staffing deficits, particularly among specialized biomedical technicians.

By standardizing output and drastically reducing the manual labor required per unit of blood, automated systems allow regional centers to do more with less. A regional supply chain officer observed that the technology allows facilities to reallocate full-time equivalent employees away from repetitive manual separation and toward higher-value tasks, such as complex immunohematology testing or donor recruitment. Furthermore, the compact physical footprint of modern automated devices—requiring just over one square meter of floor space—allows legacy facilities to scale their throughput without requiring expensive physical expansions.

This operational efficiency aligns with broader institutional ambitions. Versiti, for instance, is currently undertaking a massive expansion of its Blood Research Institute, slated to double its biomedical research capacity by December 2026. Freeing up operational capital and labor on the processing side allows organizations to reinvest in upstream innovations, from advanced cell therapies to novel treatments for blood-related diseases.

As the tenth U.S. implementation goes live, the ripple effects will be felt far beyond the laboratory floor. By turning routine whole blood donations into a reliable, high-yield source of perishable platelets, medical technology is closing a critical gap in patient care. In an era defined by supply chain volatility, the ability to extract maximum clinical value from every drop of donated blood is not just a technological triumph; it is a fundamental restructuring of how we sustain human life.